Vanguard Capital Management’s Heron Therapeutics HRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.46M Buy
7,820,161
+37,420
+0.5% +$14.2K ﹤0.01% 3316
2026
Q2
$3.32M Sell
7,782,741
-27,588
-0.4% -$22.1K ﹤0.01% 3254
2026
Q1
$6.25M Buy
+7,810,329
New +$9.05M ﹤0.01% 2968

Other funds holding HRTX

Vanguard Capital Management's HRTX Position: Q3 2026 in Review

Vanguard Capital Management increased its Heron Therapeutics (HRTX) stake by 0.48% in Q3 2026, buying an estimated $14.2K and bringing the position to 7,820,161 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3316.

Vanguard Capital Management first reported a position in HRTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $6.25M in Q1 2026. 159 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • Vanguard Capital Management held 7,820,161 shares of Heron Therapeutics worth $2.46M as of Q3 2026.
  • Vanguard Capital Management bought 37,420 Heron Therapeutics shares in Q3 2026, an estimated $14.2K.
  • Heron Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3316 holding.
  • Vanguard Capital Management first reported a position in Heron Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Heron Therapeutics position peaked at $6.25M in Q1 2026.
  • 159 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.